Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations.
about
VHL type 2B mutations retain VBC complex form and functionThe role of PHD2 mutations in the pathogenesis of erythrocytosis.Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes.Repression of PLA2R1 by c-MYC and HIF-2alpha promotes cancer growthHypoxia-inducible factors have distinct and stage-specific roles during reprogramming of human cells to pluripotency.Degradation of the deubiquitinating enzyme USP33 is mediated by p97 and the ubiquitin ligase HERC2.Genotype-phenotype correlation in ocular von Hippel-Lindau (VHL) disease: the effect of missense mutation position on ocular VHL phenotypeClinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma.VHL, the story of a tumour suppressor gene.Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinomaEpigenetic Regulation by Lysine Demethylase 5 (KDM5) Enzymes in Cancer.Quantitative image analysis identifies pVHL as a key regulator of microtubule dynamic instability.The contributions of HIF-target genes to tumor growth in RCC.New insights into the biology of renal cell carcinomaGenetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor geneCancer-causing mutations in a novel transcription-dependent nuclear export motif of VHL abrogate oxygen-dependent degradation of hypoxia-inducible factor.Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer.Proteostasis modulators prolong missense VHL protein activity and halt tumor progressionThe VHL/HIF axis in clear cell renal carcinoma.Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen.VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment.Biology of hypoxia-inducible factor-2alpha in development and diseaseSunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells.VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo.Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.Hereditary kidney cancer syndromes.Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction.SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer.pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner.Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenasesOxygen sensing and hypoxia signalling pathways in animals: the implications of physiology for cancer.Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathwaysThe relationship of cancer stem cells in urological cancers.Targeting the RhoGTPase/ROCK pathway for the treatment of VHL/HIF pathway-driven cancers.Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma.In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation.VHL loss causes spindle misorientation and chromosome instability.VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL.Regulation of renal epithelial tight junctions by the von Hippel-Lindau tumor suppressor gene involves occludin and claudin 1 and is independent of E-cadherin.Interaction between von Hippel-Lindau Protein and Fatty Acid Synthase Modulates Hypoxia Target Gene Expression.
P2860
Q21144205-FDDBFB75-B71C-49CE-91ED-2C0CF2AFDEECQ28598099-EE1A1B60-73E1-4253-AE0A-74B86D1AD9ACQ33481999-DEFCC35F-9A46-4E70-9738-381AB4595F03Q33572229-37CDDAAC-D3FD-4F77-B980-43FFA882ACE2Q33637916-0891C136-ADA5-476E-98C2-726B67CC3185Q33888656-ED0E4C7B-5F18-4024-87E3-91210240CEAAQ34135425-2135816B-ABD4-4EE3-8C83-1AAC629BF832Q34217763-DA8F60C2-57DF-4B56-8705-69CC71D51067Q34455226-B0E9E9DD-1322-451C-8C61-32C3B9302D6AQ34658963-69D95703-7624-4904-AFB9-D93F9D185FFDQ34897761-8B20CC8C-1FF0-4C4C-8478-FBD8957FFF58Q35005618-EB42A64F-5734-49FC-B1BE-B9326BEE1B9CQ35049084-9867442F-C0F5-4BF8-9980-2952FE235B01Q35180400-BC836C64-ACAD-42EB-96D6-FE0CAE0F5DD7Q35452783-1E4B87BB-7989-4A3F-9B22-5635CD863955Q36421050-80EEB415-4719-47A4-B61A-B8225C93B04AQ36518228-A2BA945B-9364-4A47-822F-1D49AA1C1E1AQ36585720-17FDACDF-8331-4CBF-9BB1-28990AB20A63Q36872295-2317FF0F-C829-4891-BEE5-BB17C4C2FEB8Q36954859-C7E4C12D-98EB-40E0-9AD8-279AA0D3197CQ37038901-AD69EA47-0D36-4B8E-B7FC-625C1C9D78AFQ37079716-2B4051B0-35BE-4FB6-9F14-62D284268AF2Q37147482-B51BD4B4-C1E8-41B7-B07A-827ED1DF347DQ37154944-0D0A6FCD-D0C1-4089-A679-1E7DED164621Q37234734-C3F85488-A0F2-4FA2-8501-2485DA0F847FQ37412363-7CB1FFE2-2D1C-4454-9A79-4BFF33CF29FFQ37464073-6E2B9163-8586-492E-9834-1A5C2C4F336EQ37542249-68C4A902-6BBD-4CE6-ADAA-718602454A8AQ37666827-0D095CEB-6649-4589-BECC-0D3663AA3464Q37957006-1BD95E33-BCE3-4B9F-A6ED-9FA1D065B3EEQ38080837-971A8D7D-13FB-4EB0-92DA-207587775FC8Q38184665-934D57C2-D90D-48F9-9115-957C2CA94456Q38202644-4DD7CF49-BD1F-4CAD-865D-303CF7E12FF0Q38668940-24E81F3B-3F74-410D-A2D8-DB56D02782AEQ38938089-76AC9C5C-ACC6-404E-BD38-9D3FFD62CFC1Q39030433-78D8588A-54B0-4A56-8D8C-564C806195AAQ39822734-C6EA4C6A-6CDE-4354-8FC7-2FAD1CB25929Q39882063-EE93275E-0F58-44FA-83C5-144DE468ABE8Q39906454-D0C8C538-44B0-4FEE-AF8A-FCD1D8B250F0Q41242833-CC6B3980-5790-4D71-B959-180035ACA2BD
P2860
Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Hypoxia-inducible factor linke ...... 2A and type 2B VHL mutations.
@en
type
label
Hypoxia-inducible factor linke ...... 2A and type 2B VHL mutations.
@en
prefLabel
Hypoxia-inducible factor linke ...... 2A and type 2B VHL mutations.
@en
P2093
P2860
P356
P1476
Hypoxia-inducible factor linke ...... e 2A and type 2B VHL mutations
@en
P2093
Aria F Olumi
Liang Zhang
Lianjie Li
Steven Bartz
William G Kaelin
Xiaoping Zhang
P2860
P304
P356
10.1128/MCB.00282-07
P407
P577
2007-05-25T00:00:00Z